| Price | 202.00p on 29-10-2026 at 19:35:13 |
|---|---|
| Change | -4.00p -1.94% |
| Buy | 212.00p |
| Sell | 203.00p |
| Last Trade: | Buy 1,604.00 at 202.00p |
| Day's Volume: | 16,796 |
| Last Close: | 202.00p |
| Open: | 203.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 202.00p - 203.00p |
| 52wk Range: | 153.00p - 239.00p |
| Market Capitalisation: | £1.76b |
| VWAP: | 203.26179p |
| Shares in Issue: | 869.07m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 1,604 | 202.00p | Suspected BUY Trade |
16:35:26 - 29-Oct-26 |
| Sell* | 238 | 203.00p | Automatic Execution |
16:28:59 - 29-Oct-26 |
| Sell* | 1 | 206.60p | Ordinary |
15:11:27 - 29-Oct-26 |
| Sell* | 101 | 207.00p | Negotiated Trade |
14:40:32 - 29-Oct-26 |
| Sell* | 377 | 203.64p | Ordinary |
12:34:34 - 29-Oct-26 |
| Buy* | 3 | 211.00p | SI Trade |
12:14:42 - 29-Oct-26 |
| Sell* | 2,428 | 205.50p | Ordinary |
12:14:31 - 29-Oct-26 |
| Sell* | 469 | 201.80p | Ordinary |
12:04:03 - 29-Oct-26 |
| Sell* | 144 | 205.614p | Negotiated Trade |
11:36:33 - 29-Oct-26 |
| Sell* | 10,000 | 202.00p | Ordinary |
09:33:22 - 29-Oct-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 29th Oct 2026 7:00 am | RNS-R | US FDA Grants Sovleplenib Orphan Drug Designation |
| 27th Oct 2026 7:00 am | RNS-R | HUTCHMED to Host Event on Recent Savolitinib Data |
| 26th Oct 2026 8:30 am | RNS-R | SANOVO Phase III Data at ESMO |
| 26th Oct 2026 7:00 am | RNS-R | SAFFRON Phase III Data ESMO & NEJM Publication |
| 21st Oct 2026 7:00 am | RNS-R | KRAS-EGFR-Antibody licensing deal with GSK closes |
| 29th Sep 2026 7:00 am | RNS-R | Submission of US NDA for ORPATHYS® plus TAGRISSO |
| 28th Sep 2026 7:00 am | RNS-R | HUTCHMED Initiates Global Trial of HMPL-A830 |
| 24th Sep 2026 7:00 am | RNS-R | Data to be Presented at ESMO 2026 |
| 3rd Sep 2026 7:00 am | RNS | HUTCHMED Licenses KRAS-EGFR-Antibody to GSK |
| 1st Sep 2026 7:00 am | RNS | SANOVO trial demonstrated significant PFS benefit |
